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Putting numbers on the End TB Strategy—an impossible 
dream? 
In 2015, WHO announced a plan to end tuberculosis 
by 2035 (their End TB Strategy)  and set ambitious 
intermediate targets to reduce tuberculosis in-
cidence by 50% and mortality by 75% by 2025.1 
In The Lancet Global Health, two related papers 
by Rein Houben2 and Nicolas Menzies3 and their 
colleagues describe the results of a unique international 
collaboration between 11 diﬀ erent tuberculosis 
modelling groups, and public health oﬃ  cials from 
national tuberculosis programmes. They assessed the 
feasibility, costs, and epidemiological outcomes of 
country-speciﬁ c interventions in India, China, and South 
Africa, and determined that these 10-year targets could 
be achievable only in South Africa with a combination of 
continuous isoniazid preventive therapy for individuals 
on antiretroviral therapy, expanded facility-based 
screening for symptoms of tuberculosis at health centres, 
and improved tuberculosis care. In China and India, 
important reductions could be achieved, but they fell 
short of the WHO targets.2 All models that considered 
costs projected the need for massive and sustained 
increases in government health spending, to more than 
three times current levels, although most judged that 
these interventions could be considered cost-eﬀ ective. 
Interestingly, all predicted that patients’ costs would be 
substantially reduced with most interventions. 
This project showed the potential value of two 
innovative collaborations toward achieving global 
tuberculosis control. First, this investigation was 
accomplished simultaneously by several diﬀ erent 
modelling groups and investigators from a total of 
ten diﬀ erent countries—in itself a major achievement! 
The modelling groups worked independently, using 
their preferred modelling approaches, but with similar 
parameters and assumptions. Readers will usually 
want to know if the ﬁ ndings are unchanged when key 
assumptions are varied in sensitivity analyses, and if 
results are similar in studies published separately by 
diﬀ erent groups. We think readers should be sceptical, 
given the grand scale of assumptions made by the 
investigators of these two studies. In these Articles,2,3 
results from 11 models are presented together—a sort of 
uber-sensitivity analysis. The results are quite consistent 
and provide a coherent message, which we ﬁ nd 
reassuring. The second innovation was the partnership 
of these modelling teams with personnel from national 
tuberculosis programmes, who were responsible for the 
selection of interventions and helping to estimate their 
expected eﬀ ects. This should make the results more 
applicable and realistic for the countries selected, while 
also enhancing knowledge translation. 
For most health-care professionals, infectious-disease 
modelling is something of a black box. One can see the 
input assumptions (ie, what goes in) and the outputs (ie, 
what comes out), but what happens in between seems 
close to magic. Given their complexity, to understand 
any one of the models used in these studies is diﬃ  cult; to 
understand the strengths and limitations of all 11 models 
might be beyond the capacity of most (if not all) readers. 
So, we must therefore accept a little magic, and rely on a 
careful review of what goes in, to decide if what comes 
out is credible. And the assumed inputs are a major 
limitation of these studies, for although the involvement 
of national tuberculosis programme oﬃ  cials in selecting 
interventions and targets was a strength, the actual 
population-level eﬀ ect, and costs, of the interventions are 
unknown. For example, active case ﬁ nding through chest 
radiography was the cornerstone of tuberculosis control 
for decades in high-income countries,4 and interest in 
active case ﬁ nding has been revived recently.5 However, 
scant published evidence of its eﬀ ect on outcomes, 
transmission, or its cost-eﬀ ectiveness is available,6 and 
therefore mass screening is not recommended by WHO.6 
The true costs of these interventions, when applied at 
national scale, are also unknown. Estimations of costs 
extrapolated from small projects might not be accurate 
for national-level interventions. For example, the ﬁ nding 
that scaling up use of the Xpert RIF/MTB assay might 
simply reﬂ ect better information, since the actual costs 
for national expansion in South Africa have been carefully 
measured,7 by contrast with the estimated costs for 
the other interventions. Even feasibility is uncertain, 
particularly for population-level interventions such as 
mass chest radiography and isoniazid preventive therapy 
in South Africa, or partnerships with the rapidly evolving 
private sector in India. 
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Overall, however, we feel the investigators used 
all currently available information, and did a careful 
and thorough analysis of innovative approaches for 
global tuberculosis control.  Although further research 
is required to better understand the epidemiological 
eﬀ ects and the enormous health-system expenditures 
that will be needed to implement these interventions 
on a large scale, this requirement should not obscure 
two important messages from these studies. First, the 
consistent ﬁ nding of substantial savings for patients is 
a reminder that reducing the tuberculosis burden is all 
about reducing the burden on patients. And second, 
that perhaps the goal of ending tuberculosis is not such 
an impossible dream. 
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